Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy

Muscle and Nerve

Volumn 52, Issue 6, 2015, Pages 942-947

  Montes, Jacqueline ^a   Glanzman, Allan M ^b   Mazzone, Elena S ^c   Martens, William B ^d   Dunaway, Sally ^a   Pasternak, Amy ^e   Riley, Susan O ^e   Quigley, Janet ^e   Pandya, Shree ^d   De Vivo, Darryl C ^a   Kaufmann, Petra ^a   Chiriboga, Claudia A ^a   Finkel, Richard S ^f   Tennekoon, Gihan I ^g   Darras, Basil T ^e   Pane, Marika ^c   Mercuri, Eugenio ^c   Mcdermott, Michael P ^d,h  

^a Department of Medicine   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NEMOURS CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Clinical trial; Composite score; Motor function; Outcome measure; SMA; Spinal muscular atrophy

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FUNCTIONAL ASSESSMENT; HAMMERSMITH FUNCTIONAL MOTOR SCALE EXPANDED; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; SIX MINUTE WALK TEST; SPINAL MUSCULAR ATROPHY; SPINAL MUSCULAR ATROPHY FUNCTIONAL COMPOSITE SCORE; UPPER LIMB MODULE; WALKING; MOVEMENT (PHYSIOLOGY); MUSCULAR ATROPHY, SPINAL; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; UPPER LIMB; YOUNG ADULT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MOVEMENT; MUSCULAR ATROPHY, SPINAL; PRINCIPAL COMPONENT ANALYSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UPPER EXTREMITY; WALKING; YOUNG ADULT;

EID: 84955188348     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24670     Document Type: Article

References (31)

1. Ludvigsson P, Olafsson E, Hauser WA. Spinal muscular atrophy. Incidence in Iceland. Neuroepidemiology 1999;18:265-269.
2. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs VM, Flynn K, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72, 400 specimens. Eur J Hum Genet 2012;20:27-32.
3. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-165.
4. Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 2012;79:1889-1897.
5. Pane M, Staccioli S, Messina S, D'Amico A, Pallicioni M, Mazzone ES, et al. Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 2008;18:536-540.
6. Kissel JT, Elsheikh B, King WM, Freimer M, Scott CB, Kolb SJ, et al. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve 2014;49:187-192.
7. Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 2003;7:155-159.
8. Glanzman AM, Mazzone E, Main M, Pellicioni M, Wood J, Swoboda KJ, et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 2010;20:155-161.
9. Glanzman AM, O'Hagen JM, McDermott MP, Martens WB, Flickinger J, Riley S, et al. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol 2011;26:1499-1507.
10. Nelson L, Owens H, Hynan LS, Iannaccone ST. The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord 2006;16:374-380.
11. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 2006;16:417-426.
12. Vuillerot C, Payan C, Girardot F, Fermanian J, Iwaz J, Bérard C, et al. Responsiveness of the motor function measure in neuromuscular diseases. Arch Phys Med Rehabil 2012;93:2251-2256.
13. Mazzone E, Bianco F, Martinelli D, Glanzman AM, Messina S, De Sanctis R, et al. Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord 2011;21:406-412.
14. Montes J, McDermott MP, Martens WB, Dunaway S, Glanzman AM, Riley S, et al. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology 2010;74:833-838.
15. Burns TM, Conaway M, Sanders DB, Composite MG, Group M-QS. The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010;74:1434-1440.
16. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005;64:1209-1214.
17. O'Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 2007;17:693-697.
18. Montes J, Dunaway S, Montgomery MJ, Sproule D, Kaufmann P, De Vivo DC, et al. Fatigue leads to gait changes in spinal muscular atrophy. Muscle Nerve 2011;43:485-488.
19. Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One 2013;8:e52512.
20. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013;48:357-368.
21. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 2001;119:256-270.
22. ATS Statement . Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
23. Montes J, Blumenschine M, Dunaway S, Alters S, Engelstat K, Rao AK, et al. Weakness and fatigue in diverse neuromuscular diseases. J Child Neurol 2013;28:1277-1283.
24. Mazzone E, Bianco F, Main M, van den Hauwe M, Ash M, de Vries R, et al. Six minute walk test in type III spinal muscular atrophy: a 12-month longitudinal study. Neuromuscul Disord 2013;23:624-628.
25. Geiger R, Strasak A, Treml B, Högler W, Stüben K, Strasak A, et al. Six-minute walk test in children and adolescents. J Pediatr 2007;150:395-399.
26. Gibbons WJ, Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil 2001;21:87-93.
27. Cano SJ, Mayhew A, Glanzman AM, Krosschell KJ, Swoboda KJ, Main M, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve 2014;49:422-430.
28. Mazzone ES, Mayhew A, Main M, Montes J, Ramsey D, Scoto M, et al. Old measures and new analysis in non ambulant SMA patients. Neuromuscul Disord 2014;24:905.
29. Sarepta Therapeutics I. 2013. Available at: http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&ID=1875187/.
30. Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, Siskind C, et al. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 2013;70:981-987.
31. Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, et al. Development of the Performance of the Upper Limb Module for Duchenne muscular dystrophy. Dev Med Child Neurol 2013;55:1038-1055.